Follows stem cell transplant patients and donors at high altitude in Tibet
Records patients receiving stem cell transplants for blood diseases, and their donors, over time.
Plain-language title generated from the registry record
Registry title: High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Key facts
- Where
- Xining, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for patients with blood diseases who are admitted to the stem cell transplant center of Qinghai University Affiliated Hospital and who plan to have or have had a stem cell transplant.
- Sex
- All sexes can join.
- Disease stage
- Blood diseases (for example leukemia, lymphoma, myelodysplastic syndrome, aplastic anemia) treated with a stem cell transplant.
- Earlier treatment
- Admitted to the transplant center on or after September 1, 2023, with a stem cell transplant planned or already done.
Main reasons for not taking part
- Cannot give long-term follow-up data because of severe other illnesses or practical reasons
- Substance abuse that affects sticking to the study
- Any condition the investigators judge a risk to safety or compliance
Read by machine on 12 November 2026.
Where in China
- Affiliated Hospital of Qinghai UniversityXining, ChinaContact: Yigeng CAO, MD,PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Yigeng Cao,MD,PhD
- Trial code
- NCT07205523
- Record updated
- 3 October 2025
- Original description
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.Read full original descriptionShow less
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.
Inclusion: Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023; Planned or actual hematopoietic stem cell transplantation (HSCT); Provision of signed informed consent.
Exclusion: Any condition judged by investigators to jeopardize safety or compliance; Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons; Substance abuse compromising adherence.